Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants

Jasper offers to buy back all 12.3 million outstanding warrants for $0.324 each.

What the company is saying

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has launched a formal tender offer to purchase any and all of its 12,345,707 outstanding warrants, each originally issued in its September 18, 2025 public offering. The company sets the cash purchase price at $0.324 per warrant, with no interest, and states the offer is aimed at reducing potential dilution from future warrant exercises. Jasper frames this as a move to provide shareholders and investors greater certainty about the company's capital structure. The offer is open until one minute after 11:59 p.m. Eastern Time on November 6, 2026, unless extended or terminated earlier, and is not subject to a minimum participation threshold. Holders may tender any amount of their warrants or choose to exercise them during the offer period. The company discloses that if all warrants are tendered, the total payout would be approximately $4.0 million, funded from cash on hand. The process is described as subject only to customary conditions, with no dealer manager, information agent, or depositary engaged. Matthew Ros, Chief Operating Officer, is named as the contact for procedural questions.

What the data suggests

The company has 12,345,707 warrants outstanding as of October 6, 2026, each entitling the holder to purchase one share of common stock at an exercise price of $2.92. The tender offer price of $0.324 per warrant represents a cash outlay of up to $4.0 million if all warrants are tendered. The warrants were originally issued in a public offering on September 18, 2025, and will expire on March 18, 2030 if not exercised or tendered. The offer is entirely discretionary for holders, with no minimum participation required. The company provides no quantitative modeling of the dilution impact or pro forma capital structure post-offer, so the precise effect on share count and dilution is not disclosed. The only financial figures provided are the par value per share ($0.0001), the warrant exercise price ($2.92), the tender offer price ($0.324), the total number of warrants, and the maximum payout. All funds for the offer are to come from existing cash. No broader financial or operational metrics are included.

Analysis

The announcement is a standard, factual disclosure of a warrant tender offer, with all key terms, dates, and procedures clearly stated. The language is procedural and does not contain promotional or exaggerated claims about future benefits or company prospects. While several statements are forward-looking (e.g., the purpose to reduce dilution, the process for retiring warrants), these are mechanical outcomes of the offer and not aspirational projections. The only capital outlay discussed is the potential $4.0 million payout, which is fully funded from cash on hand and contingent on tender participation, with no implication of long-term or uncertain returns. There is no attempt to frame the action as transformative or to overstate its impact. The gap between narrative and evidence is negligible, as all claims are either realised or directly tied to the mechanics of the offer.

Risk flags

• ●Participation in the offer is voluntary, so the actual reduction in potential dilution depends on how many warrant holders tender. If participation is low, the intended benefit to the capital structure may not be achieved.
• ●The company is committing up to $4.0 million of cash on hand to this offer, which could impact liquidity if a high percentage of warrants are tendered, though no current cash balance is disclosed.
• ●No dealer manager, information agent, or depositary has been engaged, which could affect the efficiency or clarity of the tender process and may increase the risk of procedural errors or communication issues for warrant holders.

Bottom line

Jasper Therapeutics is offering $0.324 in cash for each of its 12.3 million outstanding warrants, aiming to reduce future dilution and clarify its capital structure. The maximum payout, if all warrants are tendered, would be $4.0 million, funded from existing cash. The offer is open for one month, with no minimum participation required, and holders can choose to tender any or all of their warrants or exercise them at $2.92 per share. The company provides no modeling of the actual dilution reduction or post-offer share count, so the impact depends entirely on holder participation. The absence of a dealer manager or agent may add logistical complexity. Investors should focus on the final participation rate and resulting capital structure, as these will determine whether the offer meaningfully reduces dilution risk.

Announcement summary

(NASDAQ:JSPR) Jasper Therapeutics, Inc. has commenced an offer to purchase any and all of its outstanding warrants to purchase shares of its common stock, par value $0.0001 per share, that were issued in its underwritten public offering on September 18, 2025. The purchase price for each Warrant is $0.324 in cash, without interest. The purpose of the Offer is to reduce the number of shares of Common Stock that would become outstanding upon exercise of the Warrants, thereby reducing potential dilution and providing greater certainty regarding the Company’s capital structure. Warrants tendered in the Offer will be retired and cancelled. Each Warrant entitles its holder to purchase one share of Common Stock at an exercise price of $2.92, subject to adjustment. Holders may tender as few or as many Warrants as they choose, or may exercise their Warrants during the Offer Period in accordance with their terms. Warrants not tendered will remain outstanding on their original terms and will expire at 5:00 p.m., Eastern Time, on March 18, 2030. The Offer will remain open until one minute after 11:59 p.m., Eastern Time, on November 6, 2026, unless extended or terminated earlier by the Company. Holders may withdraw tendered Warrants at any time before the Expiration Date. The Offer is not conditioned on a minimum number of Warrants being tendered, but is subject to customary conditions described in the Offer to Purchase, including the absence of legal actions, governmental orders, or material adverse changes that would prohibit, restrict, or delay the Offer or materially impair its benefits. The Company may waive these conditions or extend, amend, or terminate the Offer, subject to applicable law. Promptly after the Expiration Date, the Company will pay the Offer Purchase Price for validly tendered and not withdrawn Warrants. If all outstanding Warrants are tendered, the Company expects to pay out approximately $4.0 million, funded from cash on hand. The Offer is being made under an Offer to Purchase dated October 7, 2026, and a Tender Offer Statement on Schedule TO dated October 7, 2026, both filed with the SEC. As of October 6, 2026, there were 12,345,707 Warrants outstanding. The Company has not engaged a dealer manager, information agent, or depositary for the Offer. Questions about tender procedures and requests for additional copies of the offer materials should be directed to Matthew Ros, Chief Operating Officer of Jasper Therapeutics, Inc.

Disagree with this article?